Research

Hormonal

GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) cause a significant reduction in skeletal muscle mass (30-40% of total weight loss), posing a risk for sarcopenia, particularly in elderly patients and those with type 2 diabetes.

If you are taking semaglutide or tirzepatide, expect to lose some muscle along with fat. To protect your strength, you must eat more protein (at least 1.2g/kg/day) and perform resistance training 2-3 times per week. This is especially critical if you are older or already have low muscle mass.

GoodSupportsHIGH confidence
Numerous studies indicate that, in addition to gastrointestinal adverse events, these medications may contribute to a reduction in muscle mass, potentially worsening the metabolic status of patients... some studies report decreases in lean mass of 40% to 60% of total weight loss... This is particularly relevant for elderly patients and those with sarcopenic obesity, for whom additional loss of muscle tissue can pose a serious risk.
В. В. Салухов et al. · Meditsinskiy sovet = Medical Council · 2025

Why this rating

Based on a review of multiple randomized clinical trials (STEP, SURPASS, SURMOUNT) and a meta-analysis of 38 studies.

Source

The impact of semaglutide and tirzepatide on skeletal muscle: Significant benefit or substantial risk?

В. В. Салухов et al. · Meditsinskiy sovet = Medical Council · 2025

DOI 10.21518/ms2025-467

narrative_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →